REPL Stock Forecast: Replimune Group, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$19
−0.83% on the day

The 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $27 — +41.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 63 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$1.8B
Ticker Nerd rank
63/ 100
Median analyst target
$27
Analysts covering
8
Revenue$0.0
Operating income−$68.0M
Net income−$69.8M
Free cash flow−$75.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.9%
1M
+67.0%
YTD
+96.2%
1Y
+111.7%
From 52W high
−18.1%
From 52W low
+1021.8%
$2
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
63/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Value
81
Growth
71
Revisions
67
Accruals
59
Volatility
52
Quality
33
Issuance
10

Momentum (88): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

REPL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26REPLHigh $31Median $27Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7
Buy
0
Hold
1
Sell
$19
Low
$27
Median
$31
High

The green dot is the last close — the median target sits +41.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026Piper SandlerMaintainsOverweight$14 → $27
29 Oct 2026Leerink PartnersMaintainsOutperform$19 → $31
26 Aug 2026JP MorganMaintainsOverweight$20 → $21
7 Aug 2026JP MorganMaintainsOverweight$17 → $20
7 Aug 2026WedbushUpgradeOutperform$12 → $19
4 Aug 2026Leerink PartnersUpgradeOutperform$11 → $17
31 July 2026Cantor FitzgeraldUpgradeOverweight—
31 July 2026WedbushMaintainsNeutral$9.00 → $12
30 June 2026WedbushMaintainsNeutral$6.00 → $9.00
26 June 2026JP MorganUpgradeOverweight—
1 June 2026WedbushMaintainsNeutral—
29 May 2026JP MorganUpgradeNeutral—
13 Apr 2026Cantor FitzgeraldDowngradeNeutral—
13 Apr 2026HC Wainwright & Co.DowngradeSell—
13 Apr 2026JefferiesDowngradeHold—
13 Apr 2026JP MorganDowngradeUnderweight—
13 Apr 2026Leerink PartnersDowngradeMarket Perform—
13 Apr 2026WedbushDowngradeNeutral—
5 Feb 2026Piper SandlerMaintainsOverweight—
4 Feb 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for REPL.

Market Radar

This page is one stock. Monday covers all of them.

REPL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

REPL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Replimune Group, Inc. returned +111.7% against +6.9% for the S&P 500, dividends included.

REPL vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26REPLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REPL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
8.8×

Cheaper than 9% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−115.8%

Higher than 12% of US stocks

Return on assets
−43.9%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Replimune Group, Inc. has a market value of $1.8B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$297.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$280.5M.

  • Shares outstanding: 84.0M.

  • Replimune Group, Inc. employs 465 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

REPL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REPLReplimune Group, Inc.$1.8B63
BHVNBiohaven Ltd.$1.8B53
VERAVera Therapeutics, Inc.$1.8B37
MRVIMaravai Lifesciences Holdings, Inc.$1.8B94
COAGHemab Therapeutics Holdings, Inc.$1.8B2
SEPNSepterna, Inc.$1.8B54
FTREFortrea Holdings, Inc.$1.8B92

Take a look at REPL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about REPL

What is the REPL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $27, with estimates ranging from $19 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REPL stock a buy right now?

Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 63 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REPL?

As at 21 Nov 2026, Replimune Group, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will REPL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +41.6% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 63 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REPL stock forecast for 2030?

No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $31 over the next 12 months.

How has REPL stock performed over the past year?

Replimune Group, Inc. returned +111.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Replimune Group, Inc. do?

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors.

Company

About Replimune Group, Inc.

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.

CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com